For patients navigating the complexities of a cancer diagnosis, the term "relapsed or refractory" carries significant weight. It marks a transition from initial treatment protocols into a more nuanced, often challenging phase of care. To address the urgent need for clarity, advocacy, and expert insight, the Lymphoma Research Foundation (LRF) is hosting a pivotal virtual program: Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease.
Scheduled for October 22, 2026, this two-hour educational summit aims to bridge the gap between complex oncological data and patient understanding, empowering those affected by lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to make informed decisions about their next steps in treatment.
Main Facts: A Vital Resource for the Lymphoma Community
The Ask the Doctor program is designed as a high-level educational forum, stripping away the jargon that often obfuscates medical literature. The event is presented in partnership with the Herbert Irving Comprehensive Cancer Center, a leader in hematologic oncology research and clinical care.
Event Logistics
- Date: Thursday, October 22, 2026
- Time: 12:00 PM – 2:00 PM ET
- Platform: Virtual via Zoom (accessible via internet or telephone)
- Target Audience: Patients, cancer survivors, care partners, and advocates.
The core of the program is its interactive structure. Rather than a static lecture, the session is built around a comprehensive expert overview followed by an extensive Q&A session, allowing attendees to address the specific anxieties and logistical questions that arise when a primary treatment fails or ceases to be effective.
Chronology: The Journey from Initial Diagnosis to Secondary Care
The path of a lymphoma patient is rarely linear. Understanding the timeline of care is essential for patients to advocate for themselves effectively.
Phase 1: Initial Diagnosis and Frontline Therapy
When a patient is first diagnosed with lymphoma or CLL/SLL, they are placed on "frontline" therapy. The goal is to induce a complete remission—the disappearance of all signs of cancer. For many, this is the end of their treatment journey.
Phase 2: The Relapse/Refractory Threshold
For a subset of patients, the disease either returns after a period of remission (relapsed) or fails to respond to the initial regimen (refractory). This phase often brings a sense of uncertainty. The medical community views this not as a failure of the patient, but as a biological shift in the disease that necessitates a change in strategy.
Phase 3: Secondary Assessment and Intervention
The upcoming program will walk attendees through this critical juncture. It will cover:
- Re-biopsy and Molecular Profiling: Why doctors need to look at the cancer again after it has recurred.
- Evaluating Novel Therapies: Shifting from standard chemotherapy to targeted agents, immunotherapies, or clinical trials.
- Supportive Care: Maintaining quality of life while navigating the emotional and physical toll of secondary treatments.
Supporting Data: Understanding the Landscape of Recurrence
While statistics vary widely depending on the specific subtype of lymphoma, the reality of recurrence is a common concern in clinical practice. The Lymphoma Research Foundation emphasizes that the landscape for relapsed/refractory (R/R) disease has evolved rapidly over the last decade.
The Shift in Treatment Paradigms
Historically, the options for patients who did not respond to initial therapy were limited. Today, the focus has shifted toward "precision medicine." According to recent clinical data, the integration of CAR T-cell therapy, bispecific antibodies, and oral targeted inhibitors has transformed the prognosis for many R/R patients.
- Targeted Therapies: Unlike broad-spectrum chemotherapy, these drugs are designed to identify and attack specific proteins on cancer cells, often resulting in fewer systemic side effects.
- Clinical Trials: The program will highlight the importance of clinical trials, which often provide access to "next-generation" therapies that are not yet available in the general market.
The expert featured for this session, Dr. Jeff Cherng, represents the intersection of clinical excellence and academic research. By featuring clinicians from top-tier institutions like the Herbert Irving Comprehensive Cancer Center, the LRF ensures that participants receive information that is grounded in the latest peer-reviewed breakthroughs.
Official Responses and Clinical Philosophy
The Lymphoma Research Foundation maintains a strict ethical boundary regarding the information provided in these sessions. It is essential for participants to understand that while the program is highly educational, it is not a substitute for clinical care.
The Disclaimer
The LRF provides a formal disclaimer for all programs: Information provided during these sessions is offered solely for educational purposes and does not constitute professional medical advice, diagnosis, or treatment.
The foundation stresses that these programs are intended to help patients "ask the right questions" during their next doctor’s appointment. By empowering patients with the correct terminology and understanding of their disease biology, the LRF aims to foster a stronger, more collaborative relationship between the patient and their personal oncologist.
Professional Engagement
For those in the pharmaceutical and oncology industries, the LRF provides specific avenues for participation. If a company is not listed as a program supporter, they are encouraged to contact the foundation directly to discuss sponsorship opportunities, ensuring that the burden of the cost for these educational programs remains minimal or nonexistent for the patients themselves.
Implications: Why This Program Matters
The implications of participating in the Ask the Doctor program extend far beyond the two hours spent on Zoom.
1. Reducing Medical Isolation
Cancer is an isolating experience. Relapsed or refractory disease can be even more isolating, as patients may feel their original treatment team has "run out of options." By connecting with experts and other patients, attendees realize that they are part of a broader, well-supported community.
2. Navigating the Information Overload
The internet is rife with medical misinformation. Patients often fall down "rabbit holes" of search results that are either outdated or irrelevant to their specific diagnosis. This program provides a curated, verified source of information, vetted by some of the world’s leading oncology experts.
3. Empowerment through Inquiry
The most significant outcome of this program is the preparation of a "question list." Patients who attend with a prepared list of questions—regarding side effects, treatment duration, and new clinical data—often report higher levels of satisfaction with their care. The program teaches attendees how to discuss complex topics like "treatment-free intervals" and "maintenance therapy" with their primary care team.
How to Participate
Registration for the October 22 event is now open. The LRF has streamlined the process to ensure accessibility for all, regardless of their technological comfort level.
- Online Registration: Participants can register through the official LRF website.
- Resource Center Support: For those who prefer personal assistance, the Lymphoma Resource Center is available at 800-500-9976 or via email at [email protected]. The staff can assist with registration, answer preliminary questions, and provide resources for those who are unable to attend the live session.
Conclusion: A Proactive Stance
A diagnosis of relapsed or refractory lymphoma is undeniably difficult, but it is not the end of the road. Modern oncology is providing more options than ever before. By attending the Ask the Doctor program, patients and their care partners are taking a proactive step toward understanding their path forward.
Whether you are currently navigating a relapse, supporting a loved one, or simply seeking to educate yourself on the potential future of lymphoma care, this session offers a rare opportunity to hear directly from the experts who are writing the protocols of tomorrow.
Remember: Knowledge is the most effective tool in the patient’s arsenal. On October 22, the Lymphoma Research Foundation is providing the tools—all that remains is for patients to bring their questions and their resilience.
For more information on the program, or to review the full patient education disclaimer, please visit the LRF official website.
